Engineered CPN1 Variants for C3a and C5a Inactivation
Solution Overview
Problem
The complement system dysregulation leads to pathological conditions such as hemolytic-uremic syndrome and cobra venom factor challenge due to deficiencies in carboxypeptidase N (CPN) and carboxypeptidase B2 (CPB2), necessitating improved regulation of C3a and C5a levels.
Innovation Solution
Development of CPN1 variants and fusion constructs with modifications, such as deletions, substitutions, and fusions, to enhance activity, stability, and affinity for C3a and C5a, allowing for effective modulation of the complement system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type CPN1 is used, then the complement system provides baseline regulation of C3a and C5a, but it results in insufficient cleavage activity to effectively treat complement-mediated diseases
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the CPN1 catalytic domain (e.g., positions 161, 188, 190, 229, 230, 281, 282, 283, 308, 320) to enhance catalytic activity. These mutations alter the enzyme's kinetic parameters to increase cleavage efficiency of C3a and C5a, directly addressing the insufficient productivity of wild type CPN1.
Solution Approach 2:
The patent creates composite protein constructs by fusing CPN1 with other proteins or protein domains (e.g., Fc regions, half-life extenders, or other catalytic domains). These fusion constructs combine the enhanced catalytic activity of modified CPN1 with the stability and pharmacokinetic properties of the fusion partner, achieving both improved productivity and reliability.
2Productivity
If CPN1 variants with enhanced catalytic activity are created, then cleavage of C3a and C5a is improved, but the complexity of protein engineering increases
Solution Approach 1:
The patent segments the CPN1 protein into functional regions (catalytic domain, regulatory domains, linkage regions) and applies targeted mutations to specific segments. This modular approach allows independent optimization of catalytic activity in the catalytic domain while maintaining the structural integrity and regulatory functions of other segments, managing complexity through systematic division.
Solution Approach 2:
The patent applies local quality by making specific point mutations at critical positions within the CPN1 catalytic domain while leaving other regions unchanged. This targeted approach enhances cleavage rate at the active site without unnecessarily complicating the entire protein structure, achieving improved productivity with minimal increase in overall complexity.
3Duration of action of stationary object
If fusion constructs are developed to improve half-life and stability, then therapeutic duration is extended, but the manufacturing complexity increases
Solution Approach 1:
The patent merges CPN1 with proteins or domains that have desirable pharmacokinetic properties (e.g., Fc regions of antibodies, albumin, or other half-life extenders). This combining strategy transfers the long half-life characteristic of the fusion partner to the CPN1 construct, extending therapeutic duration. The merging is achieved through standardized fusion techniques that, while adding complexity, leverage existing manufacturing knowledge.
Solution Approach 2:
The patent creates multi-functional fusion constructs where the fusion partner serves multiple purposes: providing half-life extension, enhancing stability, and potentially contributing to target specificity or immunogenicity control. This multi-functionality achieves extended duration of action while consolidating multiple design considerations into a single construct, managing manufacturing complexity through functional integration rather than separate modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CPN1 variants and fusion constructs increase the cleavage and inactivation of C3a and C5a, reducing complement-mediated inflammation and dysregulation, thereby treating conditions associated with overactive complement responses.
Implementation Method 1
CPN cleaves basic amino acids from the C-terminal end of bioactive peptides and proteins, leading to their inactivation. CPN inactivates C3a and C5a by cleaving one or more amino acids from their C-terminal ends.
Data Source
AI summary
Provided herein are carboxypeptidase N catalytic subunit (CPN1) variants, comprising at least one modification with respect to a wild type carboxypeptidase N1 of the M14 family, wherein the variants have at least one improved characteristic as compared to the wild type CPN1. Also provided herein are fusion constructs comprising CPN1, or variants thereof. Also provided herein are methods of making and using such variants and constructs. The variant and constructs provided herein may be useful for treating diseases or conditions associated with dysregulation of the complement system.